Belinda Edwards
Psychiatric/Mental Health · Jackson, MSNPI 1285815613
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,675 of the $28,847 with a category attached, or 64.7%. Teva Pharmaceuticals USA, Inc. accounts for 80.3% of it on its own, with 14 other manufacturers making up the rest. Among psychiatric/mental health clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 446 payments — averaging $64.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$23K
- Johnson & Johnson$970
- AbbVie$835
- Alkermes, Inc.$674
- Neurocrine Biosciences, Inc.$631
- Lundbeck LLC$585
- plus $2K from 9 others
What the payments were for
- Speaking & faculty fees$18,67565%
- Travel & lodging$1,7956%
- Food & beverage$7,85927%
- Education$5182%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 123 | $23,176 |
| Johnson & Johnson(2 entities) | 50 | $970 |
| AbbVie | 60 | $835 |
| Alkermes, Inc. | 29 | $674 |
| Neurocrine Biosciences, Inc. | 38 | $631 |
| Lundbeck LLC | 38 | $585 |
| Otsuka America Pharmaceutical, Inc. | 19 | $453 |
| Vanda Pharmaceuticals Inc. | 25 | $452 |
| E.r. Squibb & Sons, L.L.C. | 20 | $333 |
| Indivior Inc. | 16 | $271 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $223 |
| Sunovion Pharmaceuticals Inc. | 12 | $144 |
| Axsome Therapeutics, Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$20,835
- LYBALVI$458
- ABILIFY MAINTENA$123
- ABILIFY ASIMTUFII$123
- INVEGA SUSTENNA$101
How this compares
$28,847 in reported general payments places this provider in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 114 | $300,668 |
| Austedo XrDeutetrabenazine | 26 | $196,427 |
| IngrezzaValbenazine Tosylate | 21 | $177,587 |
| AristadaAripiprazole Lauroxil | 64 | $177,378 |
| Abilify MaintenaAripiprazole | 51 | $146,665 |
| Invega TrinzaPaliperidone Palmitate | 18 | $145,729 |
| UzedyRisperidone | 14 | $56,150 |
| FanaptIloperidone | 11 | $40,035 |
| Risperdal ConstaRisperidone Microspheres | 15 | $30,460 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $18,016 |
| Aripiprazole | 142 | $13,213 |
| TrintellixVortioxetine Hydrobromide | 15 | $9,670 |
| Lurasidone Hcl | 59 | $8,753 |
| Haloperidol Decanoate | 147 | $8,049 |
| Ziprasidone Hcl | 85 | $6,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $970 | $476,858147 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $23,176 | $252,57740 claims |
| Alkermes, Inc.Aristada, Lybalvi | $674 | $195,39475 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $631 | $177,58721 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $453 | $146,66551 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $452 | $40,03511 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $34 | $9,67015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Jackson
- Alanna WrightJackson$58K
- Kimberly KelleyJackson$11K
- Tyrah HickmanJackson$5K
- Min Jung KangJackson$5K
- Adriane HarveyJackson$5K
- Brandy RutlandJackson$4K
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.